Exjade (deferasirox)-Important Safety Information from Novartis as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 10/07/2008

Problem Or Issue:
Please find herewith an important safety communication from Novartis regarding Exjade (deferasirox) and hepatic failure, need for hepatic monitoring, gastrointentinal haemorrhage and ulceration, and renal tubulopathy.

« Back